COMMUNIQUÉ DE PRESSE
News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates ENIGMA-TRS 2 Phase III global clinical study in US for treatment-resistant schizophrenia with evenamide as add-on therapy. Expecting results by Q4 2026 -
COMMUNIQUÉ DE PRESSE
Family Support Now Make-or-Break for Overseas Postings, New Study Reveals
New research from AXA Global Healthcare reveals the importance of family support for international assignees, urging employers to adopt a more holistic approach. The 2025 World of Work Report emphasizes the impact on assignees' wellbeing and success criteria on global placements -
-
-
COMMUNIQUÉ DE PRESSE
New to The Street Broadcasts Tonight on Bloomberg at 6:30 PM EST Featuring Roadzen, BioVie, and TY J Young Wealth
New to The Street announces executive interviews with Roadzen, BioVie, and TY J Young Wealth on Bloomberg Television at 6:30 PM EST. Show sponsors include Laser Photonics, DataVault, Aeries Technology, Sustainable Green Team, PetVivo, and Synergy CHC -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Klöckner & Co SE: Klöckner & Co SE confirms rumors on negotiations regarding a potential voluntary public takeover offer by Worthington Steel, Inc.
Klöckner & Co SE confirms negotiations for potential public takeover offer by Worthington Steel, Inc. Due diligence review ongoing. Uncertainty on offer pursuit
